Health Care Reform 101: For Life Sciences Cos.

Law360, New York (June 17, 2010, 11:52 AM ET) -- While most of the popular press surrounding the Patient Protection and Affordable Care Act (PPACA, P.L. 111-148) and the Health Care and Education Reconciliation Act (P.L. 111-152) has focused on patients, providers and payers, the law also significantly changes how life sciences companies will do business.

Spurred by the desire to reduce health care costs while increasing quality of care, Congress has increased the government's ability to promote the development of new products and test the effectiveness of old ones. The law creates a host of...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles

Sections

Law Firms Mentioned

Government Agencies Mentioned